• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 11, 2018

View Archived Issues

Beyond the sticker shock: Policy, science needed to ensure patient access to CAR Ts

BOSTON – When Novartis AG's Kymriah (tisagenlecleucel) became the first CAR T therapy on the market after winning FDA approval last year for B-cell precursor acute lymphoblastic leukemia (ALL), the $475,000 price tag was mitigated somewhat by news that the Swiss pharma offered an outcome-based plan in which treatment would be reimbursed only when patients responded to therapy at the end of the first month. While the move ramped up discussions on how to shift the U.S. health care economics from volume-based pricing to a value-based or outcomes-based model – a change that will become increasingly necessary as more life-changing and potentially curative gene and cell therapies reach market – cost alone marks only one of the challenges in getting CAR T treatments to patients.  Read More

Hitgen nabs ¥250M series B, inks deal with Forma Therapeutics

SHANGHAI – Chengdu-based Hitgen Ltd. raised ¥250 million (US$39 million) in series B financing and inked a multi-year collaboration with Forma Therapeutics Inc, of Watertown, Mass. With a major DNA-encoded library (DEL) of small molecules, Hitgen has not found its relatively out-of-the-way location in southwestern China has held it back. Read More

Sanofi finding both opportunity and challenges on digital health frontiers

BOSTON ­– Digital health platforms and advanced computational techniques are finding increasing use in big pharma, both improving and, at times, complicating the enterprise. Though varied efforts are taking shape across the world, Rachel Sha, vice president of digital business development at Sanofi SA shed light on her company's approach at BIO International Convention. Read More

Improving data could bolster precision medicine prospects

BOSTON – How will machine learning, precision medicine and artificial intelligence (AI) affect the future of treatments? That question helped frame a panel discussion at the BIO International Convention. Much of the discussion focused on data being collected. "We talk about real-world data, and this is a buzzword," said Scott Solomon, the Edward D. Frohlich distinguished chair, professor of medicine at Harvard Medical School. He added that most real-world data are not very good, and an effort must be made to improve the quality. Read More

WHO says vaccine program is working to contain Ebola outbreak

LONDON – One month in, and the World Health Organization (WHO) is cautiously optimistic that the Ebola virus outbreak threatening the city of Mbandaka in the Democratic Republic of Congo (DRC) has been contained by the ring vaccination program that was started on May 21, 2018. Read More

Opinion cools on heated chemo during colorectal surgery after new study

CHICAGO – Debates over the value of hyperthermic intra-peritoneal chemotherapy (HIPEC) may subside as cancer patients and their doctors learn of the French study done in patients undergoing surgery for colorectal peritoneal carcinomatosis. On the other hand, maybe they won't, because fans aplenty remain. "There are surgeons in the U.S. who are firm believers in HIPEC and others who are true skeptics," said Richard Schilsky, chief medical officer of the American Society of Clinical Oncology (ASCO). "If patients travel around, they're going to hear the entire spectrum" of opinion. In such a contentious environment, "to even be able to do a randomized study is quite remarkable," he said during ASCO's annual meeting. He also noted that the surgery is "technically demanding" and "takes its toll on both the surgeon and the patient." Read More

Financings

Exact Sciences Corp., of Madison, Wisc., said that its raising up to $150 million, gross, through the sale of its 1 percent convertible senior notes, due 2025. The registered public offering is part of an earlier-announced issuance of senior notes. Read More

Other news to note

Orig3n Inc., of Boston, said it will focus on osteoarthritis indications for its cartilage regeneration program, the company's first induced pluripotent stem cells-derived cell therapy program. The company also makes consumer DNA kits. Read More

Clinical data for June 8, 2018

Read More

Regulatory actions for June 8, 2018

Read More

Bench Press: BioWorld looks at translational medicine

A team from the Canadian institution The Hospital for Sick Children and the German Cancer Research Center have discovered that antibodies binding to the malaria parasite can interact with each other as well as with their parasite target, and that this interaction improved their affinity for the pathogen.  Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe